WO1997032880A1 - PYRIMIDO[5,4-d]PYRIMIDINE, DIESE VERBINDUNGEN ENTHALTENDE ARZNEIMITTEL, DEREN VERWENDUNG UND VERFAHREN ZU IHRER HERSTELLUNG - Google Patents

PYRIMIDO[5,4-d]PYRIMIDINE, DIESE VERBINDUNGEN ENTHALTENDE ARZNEIMITTEL, DEREN VERWENDUNG UND VERFAHREN ZU IHRER HERSTELLUNG Download PDF

Info

Publication number
WO1997032880A1
WO1997032880A1 PCT/EP1997/001047 EP9701047W WO9732880A1 WO 1997032880 A1 WO1997032880 A1 WO 1997032880A1 EP 9701047 W EP9701047 W EP 9701047W WO 9732880 A1 WO9732880 A1 WO 9732880A1
Authority
WO
WIPO (PCT)
Prior art keywords
amino
group
pyrimido
methyl
pyrimidine
Prior art date
Application number
PCT/EP1997/001047
Other languages
German (de)
English (en)
French (fr)
Inventor
Frank Himmelsbach
Georg Dahmann
Thomas von Rüden
Thomas Metz
Original Assignee
Dr. Karl Thomae Gmbh
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority to UA98105276A priority Critical patent/UA54421C2/uk
Priority to AT97906152T priority patent/ATE252101T1/de
Application filed by Dr. Karl Thomae Gmbh filed Critical Dr. Karl Thomae Gmbh
Priority to DE59710864T priority patent/DE59710864D1/de
Priority to SK1208-98A priority patent/SK120898A3/sk
Priority to BR9707839A priority patent/BR9707839A/pt
Priority to NZ331545A priority patent/NZ331545A/xx
Priority to AU20945/97A priority patent/AU730376B2/en
Priority to JP9531440A priority patent/JP2000506151A/ja
Priority to EP97906152A priority patent/EP0888351B1/de
Priority to EE9800278A priority patent/EE9800278A/xx
Priority to PL97328719A priority patent/PL328719A1/xx
Priority to IL12534297A priority patent/IL125342A0/xx
Publication of WO1997032880A1 publication Critical patent/WO1997032880A1/de
Priority to NO19984082A priority patent/NO311522B1/no
Priority to BG102789A priority patent/BG63163B1/bg
Priority to HK99103458A priority patent/HK1018450A1/xx

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D487/00Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04Ortho-condensed systems
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00Drugs for dermatological disorders
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00Drugs for dermatological disorders
    • A61P17/06Antipsoriatics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
PCT/EP1997/001047 1996-03-06 1997-03-03 PYRIMIDO[5,4-d]PYRIMIDINE, DIESE VERBINDUNGEN ENTHALTENDE ARZNEIMITTEL, DEREN VERWENDUNG UND VERFAHREN ZU IHRER HERSTELLUNG WO1997032880A1 (de)

Priority Applications (15)

Application Number Priority Date Filing Date Title
EP97906152A EP0888351B1 (de) 1996-03-06 1997-03-03 PYRIMIDO 5,4-d]PYRIMIDINE, DIESE VERBINDUNGEN ENTHALTENDE ARZNEIMITTEL, DEREN VERWENDUNG UND VERFAHREN ZU IHRER HERSTELLUNG
JP9531440A JP2000506151A (ja) 1996-03-06 1997-03-03 ピリミド[5,4―d]ピリミジン、これらの化合物を含む医薬品、それらの使用及びそれらの調製方法
DE59710864T DE59710864D1 (de) 1996-03-06 1997-03-03 PYRIMIDO 5,4-d]PYRIMIDINE, DIESE VERBINDUNGEN ENTHALTENDE ARZNEIMITTEL, DEREN VERWENDUNG UND VERFAHREN ZU IHRER HERSTELLUNG
AT97906152T ATE252101T1 (de) 1996-03-06 1997-03-03 Pyrimido 5,4-d)pyrimidine, diese verbindungen enthaltende arzneimittel, deren verwendung und verfahren zu ihrer herstellung
BR9707839A BR9707839A (pt) 1996-03-06 1997-03-03 Primido-Ú5,4-D¾-primidas medicamentos contendo esses compostos sua aplicação e processo para a sua preparação
NZ331545A NZ331545A (en) 1996-03-06 1997-03-03 Pyrimido[5,4-d]pyrimidines, medicaments containing these compounds, their use and process for their production
EE9800278A EE9800278A (et) 1996-03-06 1997-03-03 Pürimido[5,4-d]pürimidiinid, neid ühendeid sisaldavad ravimid, nende kasutamine ja valmistamismeetodid
UA98105276A UA54421C2 (uk) 1996-03-06 1997-03-03 ПІРИМІДО[5,4-d]ПІРИМІДИНИ ТА ЛІКАРСЬКИЙ ЗАСІБ, ЩО МІСТИТЬ ЦІ СПОЛУКИ
SK1208-98A SK120898A3 (en) 1996-03-06 1997-03-03 Pyrimido[5,4-d]pyrimidines, medicaments containing these compounds, their use and process for their production
AU20945/97A AU730376B2 (en) 1996-03-06 1997-03-03 Pyrimido{5,4-d}pyrimidines, medicaments containing these compounds, their use and process for their production
PL97328719A PL328719A1 (en) 1996-03-06 1997-03-03 Pyrimido [5,4-d] pyrimidines, therapeutic agents containing such compounds, their application and method of obtaining such compounds
IL12534297A IL125342A0 (en) 1996-03-06 1997-03-03 Pyrimido [5,4-d] pyrimidines their preparation and pharmaceutical compositions containing them
NO19984082A NO311522B1 (no) 1996-03-06 1998-09-04 Pyrimido[5,4-d]pyrimidiner, legemiddel inneholdende disse forbindelser, deres anvendelse og fremgangsmåte for fremstillingderav
BG102789A BG63163B1 (bg) 1996-03-06 1998-09-24 Пиримидо/5,4-d/пиримидини, лекарствени средства, съдържащи тези съединения, приложението им и методза тяхното получаване
HK99103458A HK1018450A1 (en) 1996-03-06 1999-08-10 Pyrimido [5,4-d] [pyrimidines, medicaments containing these compounds, their use and process for their production

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
DE19608588A DE19608588A1 (de) 1996-03-06 1996-03-06 Pyrimido [5,4-d]pyrimidine, diese Verbindungen enthaltende Arzneimittel, deren Verwendung und Verfahren zu ihrer Herstellung
DE19608588.8 1996-03-06

Publications (1)

Publication Number Publication Date
WO1997032880A1 true WO1997032880A1 (de) 1997-09-12

Family

ID=7787345

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/EP1997/001047 WO1997032880A1 (de) 1996-03-06 1997-03-03 PYRIMIDO[5,4-d]PYRIMIDINE, DIESE VERBINDUNGEN ENTHALTENDE ARZNEIMITTEL, DEREN VERWENDUNG UND VERFAHREN ZU IHRER HERSTELLUNG

Country Status (30)

Country Link
US (1) US5821240A (no)
EP (1) EP0888351B1 (no)
JP (1) JP2000506151A (no)
KR (1) KR19990087504A (no)
CN (1) CN1064362C (no)
AR (1) AR006108A1 (no)
AT (1) ATE252101T1 (no)
AU (1) AU730376B2 (no)
BG (1) BG63163B1 (no)
BR (1) BR9707839A (no)
CA (1) CA2248720A1 (no)
CO (1) CO4650043A1 (no)
CZ (1) CZ281598A3 (no)
DE (2) DE19608588A1 (no)
EE (1) EE9800278A (no)
HK (1) HK1018450A1 (no)
HU (1) HUP9902049A3 (no)
IL (1) IL125342A0 (no)
MX (1) MX9807073A (no)
NO (1) NO311522B1 (no)
NZ (1) NZ331545A (no)
PL (1) PL328719A1 (no)
RU (1) RU2195461C2 (no)
SK (1) SK120898A3 (no)
TR (1) TR199801755T2 (no)
TW (1) TW454008B (no)
UA (1) UA54421C2 (no)
UY (1) UY24474A1 (no)
WO (1) WO1997032880A1 (no)
ZA (1) ZA971887B (no)

Cited By (83)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6414127B1 (en) 1997-11-07 2002-07-02 Isis Pharmaceuticals, Inc. Pyrimidine derivatives for labeled binding partners
WO2002079202A1 (de) * 2001-03-30 2002-10-10 Boehringer Ingelheim Pharma Gmbh & Co. Kg Verfahren zur herstellung von 4,6-diaminopyrimido[5,4-d]pyrimidinen
EP1460061A1 (en) * 2001-12-27 2004-09-22 Toray Fine Chemicals Co., Ltd. Process for producing 1-alkoxycarbonyl nitrogenous saturated heterocyclic derivative
US6867201B2 (en) * 1999-01-27 2005-03-15 Pfizer Inc Heteroaromatic bicyclic derivatives useful as anticancer agents
WO2005058913A1 (en) * 2003-12-18 2005-06-30 Janssen Pharmaceutica N.V. Pyrido- and pyrimidopyrimidine derivatives as anti- proliferative agents
WO2010026262A1 (en) * 2008-09-08 2010-03-11 Boehringer Ingelheim International Gmbh Pyrido [5, 4-d] pyrimidines as cell proliferation inhibitors
WO2010094695A1 (en) 2009-02-17 2010-08-26 Boehringer Ingelheim International Gmbh Pyrimido [5,4-d] pyrimidine derivatives for the inhibition of tyrosine kinases
WO2010099364A2 (en) 2009-02-27 2010-09-02 Osi Pharmaceuticals, Inc. Methods for the identification of agents that inhibit mesenchymal-like tumor cells or their formation
WO2010099137A2 (en) 2009-02-26 2010-09-02 Osi Pharmaceuticals, Inc. In situ methods for monitoring the emt status of tumor cells in vivo
WO2010099138A2 (en) 2009-02-27 2010-09-02 Osi Pharmaceuticals, Inc. Methods for the identification of agents that inhibit mesenchymal-like tumor cells or their formation
WO2010099139A2 (en) 2009-02-25 2010-09-02 Osi Pharmaceuticals, Inc. Combination anti-cancer therapy
WO2010099363A1 (en) 2009-02-27 2010-09-02 Osi Pharmaceuticals, Inc. Methods for the identification of agents that inhibit mesenchymal-like tumor cells or their formation
WO2010107968A1 (en) 2009-03-18 2010-09-23 Osi Pharmaceuticals, Inc. Combination cancer therapy comprising administration of an egfr inhibitor and an igf-1r inhibitor
WO2011058164A1 (en) 2009-11-13 2011-05-19 Pangaea Biotech, S.A. Molecular biomarkers for predicting response to tyrosine kinase inhibitors in lung cancer
EP2468883A1 (en) 2010-12-22 2012-06-27 Pangaea Biotech S.L. Molecular biomarkers for predicting response to tyrosine kinase inhibitors in lung cancer
EP2492688A1 (en) 2011-02-23 2012-08-29 Pangaea Biotech, S.A. Molecular biomarkers for predicting response to antitumor treatment in lung cancer
WO2012129145A1 (en) 2011-03-18 2012-09-27 OSI Pharmaceuticals, LLC Nscle combination therapy
WO2012149014A1 (en) 2011-04-25 2012-11-01 OSI Pharmaceuticals, LLC Use of emt gene signatures in cancer drug discovery, diagnostics, and treatment
US8318731B2 (en) 2007-07-27 2012-11-27 Janssen Pharmaceutica Nv Pyrrolopyrimidines
WO2013033380A1 (en) 2011-08-31 2013-03-07 Genentech, Inc. Diagnostic markers
WO2013055530A1 (en) 2011-09-30 2013-04-18 Genentech, Inc. Diagnostic methylation markers of epithelial or mesenchymal phenotype and response to egfr kinase inhibitor in tumours or tumour cells
US8492377B2 (en) 2006-07-13 2013-07-23 Janssen Pharmaceutica Nv MTKI quinazoline derivatives
WO2013152252A1 (en) 2012-04-06 2013-10-10 OSI Pharmaceuticals, LLC Combination anti-cancer therapy
WO2013190089A1 (en) 2012-06-21 2013-12-27 Pangaea Biotech, S.L. Molecular biomarkers for predicting outcome in lung cancer
US8710104B2 (en) 2008-11-07 2014-04-29 Triact Therapeutics, Inc. Catecholic butanes and use thereof for cancer therapy
WO2014147246A1 (en) 2013-03-21 2014-09-25 INSERM (Institut National de la Santé et de la Recherche Médicale) Method and pharmaceutical composition for use in the treatment of chronic liver diseases associated with a low hepcidin expression
US9134297B2 (en) 2011-01-11 2015-09-15 Icahn School Of Medicine At Mount Sinai Method and compositions for treating cancer and related methods
WO2015156674A2 (en) 2014-04-10 2015-10-15 Stichting Het Nederlands Kanker Instituut Method for treating cancer
US9381246B2 (en) 2013-09-09 2016-07-05 Triact Therapeutics, Inc. Cancer therapy
US9688691B2 (en) 2004-12-08 2017-06-27 Janssen Pharmaceutica Nv Macrocyclic quinazole derivatives and their use as MTKI
US9834575B2 (en) 2013-02-26 2017-12-05 Triact Therapeutics, Inc. Cancer therapy
WO2018119183A2 (en) 2016-12-22 2018-06-28 Amgen Inc. Kras g12c inhibitors and methods of using the same
WO2018217651A1 (en) 2017-05-22 2018-11-29 Amgen Inc. Kras g12c inhibitors and methods of using the same
WO2019051291A1 (en) 2017-09-08 2019-03-14 Amgen Inc. KRAS G12C INHIBITORS AND METHODS OF USE
WO2019213516A1 (en) 2018-05-04 2019-11-07 Amgen Inc. Kras g12c inhibitors and methods of using the same
WO2019213526A1 (en) 2018-05-04 2019-11-07 Amgen Inc. Kras g12c inhibitors and methods of using the same
WO2019217691A1 (en) 2018-05-10 2019-11-14 Amgen Inc. Kras g12c inhibitors for the treatment of cancer
WO2019232419A1 (en) 2018-06-01 2019-12-05 Amgen Inc. Kras g12c inhibitors and methods of using the same
WO2019241157A1 (en) 2018-06-11 2019-12-19 Amgen Inc. Kras g12c inhibitors for treating cancer
WO2020050890A2 (en) 2018-06-12 2020-03-12 Amgen Inc. Kras g12c inhibitors and methods of using the same
WO2020070239A1 (en) 2018-10-04 2020-04-09 INSERM (Institut National de la Santé et de la Recherche Médicale) Egfr inhibitors for treating keratodermas
WO2020102730A1 (en) 2018-11-16 2020-05-22 Amgen Inc. Improved synthesis of key intermediate of kras g12c inhibitor compound
WO2020106640A1 (en) 2018-11-19 2020-05-28 Amgen Inc. Kras g12c inhibitors and methods of using the same
WO2020106647A2 (en) 2018-11-19 2020-05-28 Amgen Inc. Combination therapy including a krasg12c inhibitor and one or more additional pharmaceutically active agents for the treatment of cancers
WO2020132653A1 (en) 2018-12-20 2020-06-25 Amgen Inc. Heteroaryl amides useful as kif18a inhibitors
WO2020132648A1 (en) 2018-12-20 2020-06-25 Amgen Inc. Kif18a inhibitors
WO2020132649A1 (en) 2018-12-20 2020-06-25 Amgen Inc. Heteroaryl amides useful as kif18a inhibitors
WO2020132651A1 (en) 2018-12-20 2020-06-25 Amgen Inc. Kif18a inhibitors
EP3699290A1 (en) 2014-12-24 2020-08-26 F. Hoffmann-La Roche AG Therapeutic, diagnostic, and prognostic methods for cancer
WO2020180768A1 (en) 2019-03-01 2020-09-10 Revolution Medicines, Inc. Bicyclic heteroaryl compounds and uses thereof
WO2020180770A1 (en) 2019-03-01 2020-09-10 Revolution Medicines, Inc. Bicyclic heterocyclyl compounds and uses thereof
WO2021026098A1 (en) 2019-08-02 2021-02-11 Amgen Inc. Kif18a inhibitors
WO2021026101A1 (en) 2019-08-02 2021-02-11 Amgen Inc. Kif18a inhibitors
WO2021026100A1 (en) 2019-08-02 2021-02-11 Amgen Inc. Pyridine derivatives as kif18a inhibitors
WO2021026099A1 (en) 2019-08-02 2021-02-11 Amgen Inc. Kif18a inhibitors
WO2021081212A1 (en) 2019-10-24 2021-04-29 Amgen Inc. Pyridopyrimidine derivatives useful as kras g12c and kras g12d inhibitors in the treatment of cancer
WO2021091967A1 (en) 2019-11-04 2021-05-14 Revolution Medicines, Inc. Ras inhibitors
WO2021091982A1 (en) 2019-11-04 2021-05-14 Revolution Medicines, Inc. Ras inhibitors
WO2021092115A1 (en) 2019-11-08 2021-05-14 Revolution Medicines, Inc. Bicyclic heteroaryl compounds and uses thereof
WO2021091956A1 (en) 2019-11-04 2021-05-14 Revolution Medicines, Inc. Ras inhibitors
WO2021097207A1 (en) 2019-11-14 2021-05-20 Amgen Inc. Improved synthesis of kras g12c inhibitor compound
WO2021097212A1 (en) 2019-11-14 2021-05-20 Amgen Inc. Improved synthesis of kras g12c inhibitor compound
WO2021108683A1 (en) 2019-11-27 2021-06-03 Revolution Medicines, Inc. Covalent ras inhibitors and uses thereof
WO2021142026A1 (en) 2020-01-07 2021-07-15 Revolution Medicines, Inc. Shp2 inhibitor dosing and methods of treating cancer
WO2021156180A1 (en) 2020-02-03 2021-08-12 Boehringer Ingelheim International Gmbh [1,3]diazino[5,4-d]pyrimidines as her2 inhibitors
WO2021156178A1 (en) 2020-02-03 2021-08-12 Boehringer Ingelheim International Gmbh [1,3]diazino[5,4-d]pyrimidines as her2 inhibitors
WO2021213800A1 (en) 2020-04-24 2021-10-28 Boehringer Ingelheim International Gmbh [1,3]DIAZINO[5,4-d]PYRIMIDINES AS HER2 INHIBITORS
WO2021257736A1 (en) 2020-06-18 2021-12-23 Revolution Medicines, Inc. Methods for delaying, preventing, and treating acquired resistance to ras inhibitors
US11236091B2 (en) 2019-05-21 2022-02-01 Amgen Inc. Solid state forms
WO2022060836A1 (en) 2020-09-15 2022-03-24 Revolution Medicines, Inc. Indole derivatives as ras inhibitors in the treatment of cancer
WO2022060583A1 (en) 2020-09-03 2022-03-24 Revolution Medicines, Inc. Use of sos1 inhibitors to treat malignancies with shp2 mutations
WO2022140427A1 (en) 2020-12-22 2022-06-30 Qilu Regor Therapeutics Inc. Sos1 inhibitors and uses thereof
US11426404B2 (en) 2019-05-14 2022-08-30 Amgen Inc. Dosing of KRAS inhibitor for treatment of cancers
WO2022235864A1 (en) 2021-05-05 2022-11-10 Revolution Medicines, Inc. Ras inhibitors
WO2022235866A1 (en) 2021-05-05 2022-11-10 Revolution Medicines, Inc. Covalent ras inhibitors and uses thereof
WO2022235870A1 (en) 2021-05-05 2022-11-10 Revolution Medicines, Inc. Ras inhibitors for the treatment of cancer
WO2023060253A1 (en) 2021-10-08 2023-04-13 Revolution Medicines, Inc. Ras inhibitors
WO2023114954A1 (en) 2021-12-17 2023-06-22 Genzyme Corporation Pyrazolopyrazine compounds as shp2 inhibitors
EP4227307A1 (en) 2022-02-11 2023-08-16 Genzyme Corporation Pyrazolopyrazine compounds as shp2 inhibitors
WO2023172940A1 (en) 2022-03-08 2023-09-14 Revolution Medicines, Inc. Methods for treating immune refractory lung cancer
WO2023240263A1 (en) 2022-06-10 2023-12-14 Revolution Medicines, Inc. Macrocyclic ras inhibitors
WO2024081916A1 (en) 2022-10-14 2024-04-18 Black Diamond Therapeutics, Inc. Methods of treating cancers using isoquinoline or 6-aza-quinoline derivatives
CN115485277B (zh) * 2020-04-24 2024-05-14 勃林格殷格翰国际有限公司 作为HER2抑制剂的[1,3]二嗪基[5,4-d]嘧啶

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL125686A (en) 1996-02-13 2002-11-10 Zeneca Ltd Quinazoline derivatives, processes for their preparation, pharmaceutical preparations containing them and their use in the manufacture of a drug with an anti-angiogenic effect and / or an effect of reducing vascular permeability
DE69709319T2 (de) 1996-03-05 2002-08-14 Astrazeneca Ab 4-anilinochinazolin derivate
US7173038B1 (en) 1999-11-05 2007-02-06 Astrazeneca Ab Quinazoline derivatives as VEGF inhibitors
EP1170011A1 (en) * 2000-07-06 2002-01-09 Boehringer Ingelheim International GmbH Novel use of inhibitors of the epidermal growth factor receptor
EP1300146A1 (en) * 2001-10-03 2003-04-09 Boehringer Ingelheim International GmbH Pharmaceutical composition for the treatment of animal mammary tumors
EP1608652A1 (en) * 2003-03-31 2005-12-28 Vernalis (Cambridge) Limited Pyrazolopyrimidine compounds and their use in medicine
JO3088B1 (ar) * 2004-12-08 2017-03-15 Janssen Pharmaceutica Nv مشتقات كوينازولين كبيرة الحلقات و استعمالها بصفتها موانع كينيز متعددة الاهداف
KR101139038B1 (ko) * 2005-06-28 2012-05-02 삼성전자주식회사 피리미도피리미딘 유도체 및 이를 이용한 유기 박막 트랜지스터
DK2170827T3 (da) * 2007-06-21 2013-11-18 Janssen Pharmaceutica Nv Indolin-2-oner og aza-indolin-2-oner
GB0713602D0 (en) * 2007-07-12 2007-08-22 Syngenta Participations Ag Chemical compounds
JP2009215259A (ja) * 2008-03-12 2009-09-24 Ube Ind Ltd 3−ハロゲノ−4−ヒドロカルビルオキシニトロベンゼン化合物の製造方法

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0055444A2 (de) * 1980-12-27 1982-07-07 Dr. Karl Thomae GmbH Trisubstituierte Pyrimido(5,4-d)pyrimidine, ihre Herstellung und diese enthaltende Arzneimittel
DE4431867A1 (de) * 1994-09-07 1996-03-14 Thomae Gmbh Dr K Pyrimido[5,4-d]pyrimidine, diese Verbindungen enthaltende Arzneimittel, deren Verwendung und Verfahren zu ihrer Herstellung

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TW414798B (en) * 1994-09-07 2000-12-11 Thomae Gmbh Dr K Pyrimido (5,4-d) pyrimidines, medicaments comprising these compounds, their use and processes for their preparation

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0055444A2 (de) * 1980-12-27 1982-07-07 Dr. Karl Thomae GmbH Trisubstituierte Pyrimido(5,4-d)pyrimidine, ihre Herstellung und diese enthaltende Arzneimittel
DE4431867A1 (de) * 1994-09-07 1996-03-14 Thomae Gmbh Dr K Pyrimido[5,4-d]pyrimidine, diese Verbindungen enthaltende Arzneimittel, deren Verwendung und Verfahren zu ihrer Herstellung

Cited By (125)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6951931B2 (en) 1997-11-07 2005-10-04 Isis Pharmaceuticals, Inc. Pyrimidine derivatives for labeled binding partners
US6800743B2 (en) 1997-11-07 2004-10-05 Isis Pharmaceuticals, Inc. Pyrimidine derivatives for labeled binding partners
US6414127B1 (en) 1997-11-07 2002-07-02 Isis Pharmaceuticals, Inc. Pyrimidine derivatives for labeled binding partners
US7511125B2 (en) 1997-11-07 2009-03-31 Carlsbad Pyrimidine derivatives for labeled binding partners
US6867201B2 (en) * 1999-01-27 2005-03-15 Pfizer Inc Heteroaromatic bicyclic derivatives useful as anticancer agents
US6849734B2 (en) 2001-03-30 2005-02-01 Boehringer Ingelheim Pharma Kg Intermediates useful for preparing 4,6-diaminopyrido[5,4-d]pyrimidines
WO2002079202A1 (de) * 2001-03-30 2002-10-10 Boehringer Ingelheim Pharma Gmbh & Co. Kg Verfahren zur herstellung von 4,6-diaminopyrimido[5,4-d]pyrimidinen
US6680384B2 (en) 2001-03-30 2004-01-20 Boehringer Ingelheim Pharma Kg Process for preparing 4,6-diaminopyrimido[5,4-d]pyrimidines
EP1460061A4 (en) * 2001-12-27 2006-05-31 Toray Finechemicals Co Ltd PROCESS FOR PRODUCING 1-ALCOXYCARBONYL SATURATED NITROGENIC HETEROCYCLIC DERIVATIVE
EP1460061A1 (en) * 2001-12-27 2004-09-22 Toray Fine Chemicals Co., Ltd. Process for producing 1-alkoxycarbonyl nitrogenous saturated heterocyclic derivative
WO2005058913A1 (en) * 2003-12-18 2005-06-30 Janssen Pharmaceutica N.V. Pyrido- and pyrimidopyrimidine derivatives as anti- proliferative agents
US7799772B2 (en) 2003-12-18 2010-09-21 Janssen Pharmaceutica N.V. Pyrido-and pyrimidopyrimidine derivatives as anti-profilerative agents
US8772272B2 (en) 2003-12-18 2014-07-08 Janssen Pharmaceutica Nv Pyrido-and pyrimidopyrimidine derivatives as anti-proliferative agents
US8933067B2 (en) 2003-12-18 2015-01-13 Janssen Pharmaceutica Nv Pyrido and pyrimidopyrimidine derivatives as anti-profilerative agents
EA013904B1 (ru) * 2003-12-18 2010-08-30 Янссен Фармацевтика Н.В. Пиридо- и пиримидопиримидиновые производные в качестве антипролиферативных агентов
NO337701B1 (no) * 2003-12-18 2016-06-06 Janssen Pharmaceutica Nv Pyrido- og pyrimido-pyrimidinderivater samt anvendelse derav i anti-celleproliferative medikamenter
US9688691B2 (en) 2004-12-08 2017-06-27 Janssen Pharmaceutica Nv Macrocyclic quinazole derivatives and their use as MTKI
US10208062B2 (en) 2004-12-08 2019-02-19 Janssen Pharmaceutica Nv Macrocyclic quinazole derivatives and their use as MTKI
US8492377B2 (en) 2006-07-13 2013-07-23 Janssen Pharmaceutica Nv MTKI quinazoline derivatives
US8318731B2 (en) 2007-07-27 2012-11-27 Janssen Pharmaceutica Nv Pyrrolopyrimidines
WO2010026262A1 (en) * 2008-09-08 2010-03-11 Boehringer Ingelheim International Gmbh Pyrido [5, 4-d] pyrimidines as cell proliferation inhibitors
US8653087B2 (en) 2008-09-08 2014-02-18 Boehringer Ingelheim International Gmbh Pyrido [5, 4-D] pyrimidines as cell proliferation inhibitors
US8710104B2 (en) 2008-11-07 2014-04-29 Triact Therapeutics, Inc. Catecholic butanes and use thereof for cancer therapy
WO2010094695A1 (en) 2009-02-17 2010-08-26 Boehringer Ingelheim International Gmbh Pyrimido [5,4-d] pyrimidine derivatives for the inhibition of tyrosine kinases
US8569316B2 (en) 2009-02-17 2013-10-29 Boehringer Ingelheim International Gmbh Pyrimido [5,4-D] pyrimidine derivatives for the inhibition of tyrosine kinases
WO2010099139A2 (en) 2009-02-25 2010-09-02 Osi Pharmaceuticals, Inc. Combination anti-cancer therapy
WO2010099137A2 (en) 2009-02-26 2010-09-02 Osi Pharmaceuticals, Inc. In situ methods for monitoring the emt status of tumor cells in vivo
WO2010099363A1 (en) 2009-02-27 2010-09-02 Osi Pharmaceuticals, Inc. Methods for the identification of agents that inhibit mesenchymal-like tumor cells or their formation
WO2010099138A2 (en) 2009-02-27 2010-09-02 Osi Pharmaceuticals, Inc. Methods for the identification of agents that inhibit mesenchymal-like tumor cells or their formation
WO2010099364A2 (en) 2009-02-27 2010-09-02 Osi Pharmaceuticals, Inc. Methods for the identification of agents that inhibit mesenchymal-like tumor cells or their formation
WO2010107968A1 (en) 2009-03-18 2010-09-23 Osi Pharmaceuticals, Inc. Combination cancer therapy comprising administration of an egfr inhibitor and an igf-1r inhibitor
WO2011058164A1 (en) 2009-11-13 2011-05-19 Pangaea Biotech, S.A. Molecular biomarkers for predicting response to tyrosine kinase inhibitors in lung cancer
WO2012085229A1 (en) 2010-12-22 2012-06-28 Pangaea Biotech, S.L. Molecular biomarkers for predicting response to tyrosine kinase inhibitors in lung cancer
EP2468883A1 (en) 2010-12-22 2012-06-27 Pangaea Biotech S.L. Molecular biomarkers for predicting response to tyrosine kinase inhibitors in lung cancer
US9494572B2 (en) 2011-01-11 2016-11-15 Icahn School Of Medicine At Mount Sinai Method and compositions for treating cancer and related methods
US9134297B2 (en) 2011-01-11 2015-09-15 Icahn School Of Medicine At Mount Sinai Method and compositions for treating cancer and related methods
WO2012113819A1 (en) 2011-02-23 2012-08-30 Pangaea Biotech, S.L. Molecular biomarkers for predicting response to antitumor treatment in lung cancer
EP2492688A1 (en) 2011-02-23 2012-08-29 Pangaea Biotech, S.A. Molecular biomarkers for predicting response to antitumor treatment in lung cancer
WO2012129145A1 (en) 2011-03-18 2012-09-27 OSI Pharmaceuticals, LLC Nscle combination therapy
WO2012149014A1 (en) 2011-04-25 2012-11-01 OSI Pharmaceuticals, LLC Use of emt gene signatures in cancer drug discovery, diagnostics, and treatment
WO2013033380A1 (en) 2011-08-31 2013-03-07 Genentech, Inc. Diagnostic markers
WO2013055530A1 (en) 2011-09-30 2013-04-18 Genentech, Inc. Diagnostic methylation markers of epithelial or mesenchymal phenotype and response to egfr kinase inhibitor in tumours or tumour cells
WO2013152252A1 (en) 2012-04-06 2013-10-10 OSI Pharmaceuticals, LLC Combination anti-cancer therapy
WO2013190089A1 (en) 2012-06-21 2013-12-27 Pangaea Biotech, S.L. Molecular biomarkers for predicting outcome in lung cancer
US9834575B2 (en) 2013-02-26 2017-12-05 Triact Therapeutics, Inc. Cancer therapy
WO2014147246A1 (en) 2013-03-21 2014-09-25 INSERM (Institut National de la Santé et de la Recherche Médicale) Method and pharmaceutical composition for use in the treatment of chronic liver diseases associated with a low hepcidin expression
US9381246B2 (en) 2013-09-09 2016-07-05 Triact Therapeutics, Inc. Cancer therapy
WO2015156674A2 (en) 2014-04-10 2015-10-15 Stichting Het Nederlands Kanker Instituut Method for treating cancer
EP3699290A1 (en) 2014-12-24 2020-08-26 F. Hoffmann-La Roche AG Therapeutic, diagnostic, and prognostic methods for cancer
WO2018119183A2 (en) 2016-12-22 2018-06-28 Amgen Inc. Kras g12c inhibitors and methods of using the same
EP4001269A1 (en) 2016-12-22 2022-05-25 Amgen Inc. Benzoisothiazole, isothiazolo[3,4-b]pyridine, quinazoline, phthalazine, pyrido[2,3-d]pyridazine and pyrido[2,3-d]pyrimidine derivatives as kras g12c inhibitors for treating lung, pancreatic or colorectal cancer
US11285135B2 (en) 2016-12-22 2022-03-29 Amgen Inc. KRAS G12C inhibitors and methods of using the same
US10532042B2 (en) 2016-12-22 2020-01-14 Amgen Inc. KRAS G12C inhibitors and methods of using the same
EP3974429A1 (en) 2017-05-22 2022-03-30 Amgen Inc. Precursors of kras g12c inhibitors
WO2018217651A1 (en) 2017-05-22 2018-11-29 Amgen Inc. Kras g12c inhibitors and methods of using the same
US10519146B2 (en) 2017-05-22 2019-12-31 Amgen Inc. KRAS G12C inhibitors and methods of using the same
US11905281B2 (en) 2017-05-22 2024-02-20 Amgen Inc. KRAS G12C inhibitors and methods of using the same
WO2019051291A1 (en) 2017-09-08 2019-03-14 Amgen Inc. KRAS G12C INHIBITORS AND METHODS OF USE
US11306087B2 (en) 2017-09-08 2022-04-19 Amgen Inc. Inhibitors of KRAS G12C and methods of using the same
EP4141005A1 (en) 2017-09-08 2023-03-01 Amgen Inc. Inhibitors of kras g12c and methods of using the same
US10640504B2 (en) 2017-09-08 2020-05-05 Amgen Inc. Inhibitors of KRAS G12C and methods of using the same
WO2019213526A1 (en) 2018-05-04 2019-11-07 Amgen Inc. Kras g12c inhibitors and methods of using the same
WO2019213516A1 (en) 2018-05-04 2019-11-07 Amgen Inc. Kras g12c inhibitors and methods of using the same
US11090304B2 (en) 2018-05-04 2021-08-17 Amgen Inc. KRAS G12C inhibitors and methods of using the same
US11045484B2 (en) 2018-05-04 2021-06-29 Amgen Inc. KRAS G12C inhibitors and methods of using the same
US11766436B2 (en) 2018-05-04 2023-09-26 Amgen Inc. KRAS G12C inhibitors and methods of using the same
WO2019217691A1 (en) 2018-05-10 2019-11-14 Amgen Inc. Kras g12c inhibitors for the treatment of cancer
US10988485B2 (en) 2018-05-10 2021-04-27 Amgen Inc. KRAS G12C inhibitors and methods of using the same
WO2019232419A1 (en) 2018-06-01 2019-12-05 Amgen Inc. Kras g12c inhibitors and methods of using the same
US11096939B2 (en) 2018-06-01 2021-08-24 Amgen Inc. KRAS G12C inhibitors and methods of using the same
WO2019241157A1 (en) 2018-06-11 2019-12-19 Amgen Inc. Kras g12c inhibitors for treating cancer
EP4268898A2 (en) 2018-06-11 2023-11-01 Amgen Inc. Kras g12c inhibitors for treating cancer
WO2020050890A2 (en) 2018-06-12 2020-03-12 Amgen Inc. Kras g12c inhibitors and methods of using the same
US11285156B2 (en) 2018-06-12 2022-03-29 Amgen Inc. Substituted piperazines as KRAS G12C inhibitors
WO2020070239A1 (en) 2018-10-04 2020-04-09 INSERM (Institut National de la Santé et de la Recherche Médicale) Egfr inhibitors for treating keratodermas
WO2020102730A1 (en) 2018-11-16 2020-05-22 Amgen Inc. Improved synthesis of key intermediate of kras g12c inhibitor compound
US11299491B2 (en) 2018-11-16 2022-04-12 Amgen Inc. Synthesis of key intermediate of KRAS G12C inhibitor compound
EP4234546A2 (en) 2018-11-16 2023-08-30 Amgen Inc. Improved synthesis of key intermediate of kras g12c inhibitor compound
WO2020106640A1 (en) 2018-11-19 2020-05-28 Amgen Inc. Kras g12c inhibitors and methods of using the same
US11053226B2 (en) 2018-11-19 2021-07-06 Amgen Inc. KRAS G12C inhibitors and methods of using the same
US11918584B2 (en) 2018-11-19 2024-03-05 Amgen Inc. Combination therapy including a KRASG12C inhibitor and one or more additional pharmaceutically active agents for the treatment of cancers
WO2020106647A2 (en) 2018-11-19 2020-05-28 Amgen Inc. Combination therapy including a krasg12c inhibitor and one or more additional pharmaceutically active agents for the treatment of cancers
US11439645B2 (en) 2018-11-19 2022-09-13 Amgen Inc. Combination therapy including a KRASG12C inhibitor and one or more additional pharmaceutically active agents for the treatment of cancers
WO2020132651A1 (en) 2018-12-20 2020-06-25 Amgen Inc. Kif18a inhibitors
WO2020132653A1 (en) 2018-12-20 2020-06-25 Amgen Inc. Heteroaryl amides useful as kif18a inhibitors
WO2020132649A1 (en) 2018-12-20 2020-06-25 Amgen Inc. Heteroaryl amides useful as kif18a inhibitors
US11236069B2 (en) 2018-12-20 2022-02-01 Amgen Inc. KIF18A inhibitors
WO2020132648A1 (en) 2018-12-20 2020-06-25 Amgen Inc. Kif18a inhibitors
WO2020180770A1 (en) 2019-03-01 2020-09-10 Revolution Medicines, Inc. Bicyclic heterocyclyl compounds and uses thereof
WO2020180768A1 (en) 2019-03-01 2020-09-10 Revolution Medicines, Inc. Bicyclic heteroaryl compounds and uses thereof
US11426404B2 (en) 2019-05-14 2022-08-30 Amgen Inc. Dosing of KRAS inhibitor for treatment of cancers
US11236091B2 (en) 2019-05-21 2022-02-01 Amgen Inc. Solid state forms
US11827635B2 (en) 2019-05-21 2023-11-28 Amgen Inc. Solid state forms
WO2021026098A1 (en) 2019-08-02 2021-02-11 Amgen Inc. Kif18a inhibitors
WO2021026099A1 (en) 2019-08-02 2021-02-11 Amgen Inc. Kif18a inhibitors
WO2021026101A1 (en) 2019-08-02 2021-02-11 Amgen Inc. Kif18a inhibitors
WO2021026100A1 (en) 2019-08-02 2021-02-11 Amgen Inc. Pyridine derivatives as kif18a inhibitors
WO2021081212A1 (en) 2019-10-24 2021-04-29 Amgen Inc. Pyridopyrimidine derivatives useful as kras g12c and kras g12d inhibitors in the treatment of cancer
WO2021091956A1 (en) 2019-11-04 2021-05-14 Revolution Medicines, Inc. Ras inhibitors
WO2021091967A1 (en) 2019-11-04 2021-05-14 Revolution Medicines, Inc. Ras inhibitors
WO2021091982A1 (en) 2019-11-04 2021-05-14 Revolution Medicines, Inc. Ras inhibitors
WO2021092115A1 (en) 2019-11-08 2021-05-14 Revolution Medicines, Inc. Bicyclic heteroaryl compounds and uses thereof
WO2021097207A1 (en) 2019-11-14 2021-05-20 Amgen Inc. Improved synthesis of kras g12c inhibitor compound
WO2021097212A1 (en) 2019-11-14 2021-05-20 Amgen Inc. Improved synthesis of kras g12c inhibitor compound
WO2021108683A1 (en) 2019-11-27 2021-06-03 Revolution Medicines, Inc. Covalent ras inhibitors and uses thereof
WO2021142026A1 (en) 2020-01-07 2021-07-15 Revolution Medicines, Inc. Shp2 inhibitor dosing and methods of treating cancer
WO2021156180A1 (en) 2020-02-03 2021-08-12 Boehringer Ingelheim International Gmbh [1,3]diazino[5,4-d]pyrimidines as her2 inhibitors
WO2021156178A1 (en) 2020-02-03 2021-08-12 Boehringer Ingelheim International Gmbh [1,3]diazino[5,4-d]pyrimidines as her2 inhibitors
WO2021213800A1 (en) 2020-04-24 2021-10-28 Boehringer Ingelheim International Gmbh [1,3]DIAZINO[5,4-d]PYRIMIDINES AS HER2 INHIBITORS
CN115485277B (zh) * 2020-04-24 2024-05-14 勃林格殷格翰国际有限公司 作为HER2抑制剂的[1,3]二嗪基[5,4-d]嘧啶
US11608343B2 (en) 2020-04-24 2023-03-21 Boehringer Ingelheim International Gmbh Substituted pyrimido[5,4-d]pyrimidines as HER2 inhibitors
CN115485277A (zh) * 2020-04-24 2022-12-16 勃林格殷格翰国际有限公司 作为HER2抑制剂的[1,3]二嗪基[5,4-d]嘧啶
WO2021257736A1 (en) 2020-06-18 2021-12-23 Revolution Medicines, Inc. Methods for delaying, preventing, and treating acquired resistance to ras inhibitors
WO2022060583A1 (en) 2020-09-03 2022-03-24 Revolution Medicines, Inc. Use of sos1 inhibitors to treat malignancies with shp2 mutations
WO2022060836A1 (en) 2020-09-15 2022-03-24 Revolution Medicines, Inc. Indole derivatives as ras inhibitors in the treatment of cancer
WO2022140427A1 (en) 2020-12-22 2022-06-30 Qilu Regor Therapeutics Inc. Sos1 inhibitors and uses thereof
WO2022235866A1 (en) 2021-05-05 2022-11-10 Revolution Medicines, Inc. Covalent ras inhibitors and uses thereof
WO2022235870A1 (en) 2021-05-05 2022-11-10 Revolution Medicines, Inc. Ras inhibitors for the treatment of cancer
WO2022235864A1 (en) 2021-05-05 2022-11-10 Revolution Medicines, Inc. Ras inhibitors
WO2023060253A1 (en) 2021-10-08 2023-04-13 Revolution Medicines, Inc. Ras inhibitors
WO2023114954A1 (en) 2021-12-17 2023-06-22 Genzyme Corporation Pyrazolopyrazine compounds as shp2 inhibitors
EP4227307A1 (en) 2022-02-11 2023-08-16 Genzyme Corporation Pyrazolopyrazine compounds as shp2 inhibitors
WO2023172940A1 (en) 2022-03-08 2023-09-14 Revolution Medicines, Inc. Methods for treating immune refractory lung cancer
WO2023240263A1 (en) 2022-06-10 2023-12-14 Revolution Medicines, Inc. Macrocyclic ras inhibitors
WO2024081916A1 (en) 2022-10-14 2024-04-18 Black Diamond Therapeutics, Inc. Methods of treating cancers using isoquinoline or 6-aza-quinoline derivatives

Also Published As

Publication number Publication date
PL328719A1 (en) 1999-02-15
BG63163B1 (bg) 2001-05-31
ZA971887B (en) 1998-09-07
UY24474A1 (es) 2000-09-29
DE59710864D1 (de) 2003-11-20
HUP9902049A3 (en) 2000-03-28
RU2195461C2 (ru) 2002-12-27
UA54421C2 (uk) 2003-03-17
JP2000506151A (ja) 2000-05-23
HK1018450A1 (en) 1999-12-24
SK120898A3 (en) 1999-02-11
IL125342A0 (en) 1999-03-12
CO4650043A1 (es) 1998-09-03
EE9800278A (et) 1999-02-15
HUP9902049A2 (hu) 1999-10-28
DE19608588A1 (de) 1997-09-11
EP0888351B1 (de) 2003-10-15
CA2248720A1 (en) 1997-09-12
BR9707839A (pt) 1999-07-27
CN1064362C (zh) 2001-04-11
CN1212694A (zh) 1999-03-31
NZ331545A (en) 2000-03-27
KR19990087504A (ko) 1999-12-27
ATE252101T1 (de) 2003-11-15
AU2094597A (en) 1997-09-22
AU730376B2 (en) 2001-03-08
TW454008B (en) 2001-09-11
NO984082D0 (no) 1998-09-04
BG102789A (en) 1999-09-30
AR006108A1 (es) 1999-08-11
EP0888351A1 (de) 1999-01-07
NO311522B1 (no) 2001-12-03
CZ281598A3 (cs) 1999-02-17
TR199801755T2 (xx) 1998-12-21
MX9807073A (es) 1998-12-31
NO984082L (no) 1998-09-04
US5821240A (en) 1998-10-13

Similar Documents

Publication Publication Date Title
EP0888351B1 (de) PYRIMIDO 5,4-d]PYRIMIDINE, DIESE VERBINDUNGEN ENTHALTENDE ARZNEIMITTEL, DEREN VERWENDUNG UND VERFAHREN ZU IHRER HERSTELLUNG
EP0779888B1 (de) Pyrimido [5,4-d]pyrimidine, diese verbindungen enthaltende arzneimittel, deren verwendung und verfahren zu ihrer herstellung
WO1997032882A1 (de) PYRIMIDO[5,4-d]PYRIMIDINE, DIESE VERBINDUNGEN ENTHALTENDE ARZNEIMITTEL, DEREN VERWENDUNG UND VERFAHREN ZU IHRER HERSTELLUNG
DE69922823T2 (de) 6-SUBSTITUIERTE PYRAZOLO(3,4-d)PYRIMIDIN-4-ONE VERWENDBAR ALS CYCLIN-ABHÄNGIGE KINASEHEMMER
EP0885226A1 (de) 4-amino-pyrimidin-derivate, diese verbindungen enthaltende arzneimittel, deren verwendung und verfahren zu ihrer herstellung
DE10042059A1 (de) Bicyclische Heterocyclen, diese Verbindungen enthaltende Arzneimittel, deren Verwendung und Verfahren zu ihrer Herstellung
EP1280798A1 (de) Bicyclische heterocyclen, diese verbindungen enthaltende arzneimittel, deren verwendung und verfahren zu ihrer herstellung
WO1996029331A1 (de) Imidazochinazoline, diese verbindungen enthaltende arzneimittel, deren verwendung und verfahren zu ihrer herstellung
DE19911510A1 (de) Bicyclische Heterocyclen, diese Verbindungen enthaltende Arzneimittel, deren Verwendung und Verfahren zu ihrer Herstellung
WO2008095847A1 (de) Bicyclische heterocyclen, diese verbindungen enthaltende arzneimittel, deren verwendung und verfahren zu ihrer herstellung
EP1379501A1 (de) In 6-stellung substituierte indoline und ihre verwendung als kinase-inhibitoren
DE19521386A1 (de) Pyrimido/5,4-d/pyrimidine, diese Verbindungen enthaltende Arzneimittel, deren Verwendung und Verfahren zu ihrer Herstellung
DE4431867A1 (de) Pyrimido[5,4-d]pyrimidine, diese Verbindungen enthaltende Arzneimittel, deren Verwendung und Verfahren zu ihrer Herstellung
DE19608631A1 (de) 4-Amino-pyrimidin-Derivate, diese Verbindungen enthaltende Arnzeimittel, deren Verwendung und Verfahren zu ihrer Herstellung
KR100395271B1 (ko) 피리미도[5,4-d]피리미딘및이를포함하는약제
DE19510019A1 (de) Imidazo[4,5-g]chinazoline, diese Verbindungen enthaltende Arzneimittel, deren Verwendung und Verfahren zu ihrer Herstellung

Legal Events

Date Code Title Description
WWE Wipo information: entry into national phase

Ref document number: 97192784.7

Country of ref document: CN

AK Designated states

Kind code of ref document: A1

Designated state(s): AL AM AT AU AZ BA BB BG BR BY CA CH CN CU CZ DE DK EE ES FI GB GE HU IL IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MD MG MK MN MW MX NO NZ PL PT RO RU SD SE SG SI SK TJ TM TR TT UA UG UZ VN YU AM AZ BY KG KZ MD RU TJ TM

AL Designated countries for regional patents

Kind code of ref document: A1

Designated state(s): GH KE LS MW SD SZ UG AT BE CH DE DK ES FI FR GB GR IE IT LU MC NL PT SE BF BJ CF

DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
121 Ep: the epo has been informed by wipo that ep was designated in this application
WWE Wipo information: entry into national phase

Ref document number: 1997906152

Country of ref document: EP

WWE Wipo information: entry into national phase

Ref document number: 1199800703

Country of ref document: VN

WWE Wipo information: entry into national phase

Ref document number: 98-01319

Country of ref document: RO

WWE Wipo information: entry into national phase

Ref document number: 331545

Country of ref document: NZ

WWE Wipo information: entry into national phase

Ref document number: PA/A/1998/007073

Country of ref document: MX

WWE Wipo information: entry into national phase

Ref document number: 120898

Country of ref document: SK

ENP Entry into the national phase

Ref document number: 2248720

Country of ref document: CA

Ref document number: 2248720

Country of ref document: CA

Kind code of ref document: A

WWE Wipo information: entry into national phase

Ref document number: PV1998-2815

Country of ref document: CZ

Ref document number: 1019980706935

Country of ref document: KR

Ref document number: 1998/01755

Country of ref document: TR

WWP Wipo information: published in national office

Ref document number: 1997906152

Country of ref document: EP

WWP Wipo information: published in national office

Ref document number: PV1998-2815

Country of ref document: CZ

REG Reference to national code

Ref country code: DE

Ref legal event code: 8642

WWP Wipo information: published in national office

Ref document number: 1019980706935

Country of ref document: KR

WWG Wipo information: grant in national office

Ref document number: 1997906152

Country of ref document: EP

WWR Wipo information: refused in national office

Ref document number: PV1998-2815

Country of ref document: CZ

WWR Wipo information: refused in national office

Ref document number: 1019980706935

Country of ref document: KR